One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in ...

The rate of mpox infection in the vaccinated group was 0.09 for every 1,000 person-days as compared to 0.20 in the ...

On September 13, 2024, the World Health Organization (WHO) announced that it added the first vaccine against monkeypox (mpox) to its ...

"This study reinforces the benefit in vaccinating against mpox with MVA-BN and reaffirms that a single dose provides at least ...

The African health agency says that Rwanda has started a vaccination campaign against mpox with 1,000 doses it obtained from ...

The World Health Organization (WHO) has authorized the MVA-BN vaccine as the first vaccine against mpox to be added to its ...

MVA-BN is approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA. This is the second EMA approval of an MVA-BN-based vaccine for a younger ...

The World Health Organization Friday approved MVA-BN as the first mpox vaccine added to its pre-qualification list.

The World Health Organization (WHO) has announced the MVA-BN vaccine as the first vaccine against mpox to be added to its prequalification list. The prequalification approval is expected to ...

(RTTNews) - Bavarian Nordic A/S (BAVA) Thursday said that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II ...

In an emulated target trial, a single dose of modified vaccinia Ankara-Bavarian Nordic vaccine was moderately effective in ...

In a recent study, one dose of modified vaccinia Ankara-Bavarian Nordic vaccine had estimated vaccine effectiveness of 58%. HealthDay News — One dose of modified vaccinia Ankara-Bavarian Nordic ...